Follow The Ratings: Is It Finally Time To Sell? Credit Suisse Downgrades Diplomat Pharmacy (NYSE:DPLO)

November 23, 2016 - By Ruchi Gupta

Follow The Ratings: Is It Finally Time To Sell? Credit Suisse Downgrades Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy (NYSE:DPLO) Downgrade

Equity research analysts at Credit Suisse’s equities division decreased Diplomat Pharmacy (NYSE:DPLO)‘s stock rating from “Neutral” to “Underperform” on 23 November.

Diplomat Pharmacy Inc (NYSE:DPLO) Ratings Coverage

Out of 9 analysts covering Diplomat Pharmacy (NYSE:DPLO), 2 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 22% are positive. $55 is the highest target while $17 is the lowest. The $32.43 average target is 124.90% above today’s ($14.42) stock price. Diplomat Pharmacy has been the topic of 16 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The company was downgraded on Thursday, November 3 by Avondale. The rating was upgraded by Bank of America on Wednesday, October 14 to “Neutral”. UBS initiated the stock with “Buy” rating in Wednesday, October 21 report. Mizuho maintained Diplomat Pharmacy Inc (NYSE:DPLO) rating on Thursday, November 3. Mizuho has “Neutral” rating and $17 price target. On Tuesday, June 7 the stock rating was maintained by Bank of America with “Neutral”. Raymond James downgraded the stock to “Market Perform” rating in Thursday, November 3 report. Cowen & Co maintained the shares of DPLO in a report on Thursday, November 3 with “Market Perform” rating. The rating was downgraded by Leerink Swann on Thursday, November 3 to “Mkt Perform”. Morgan Stanley downgraded it to “Equal-Weight” rating and $31 target price in Friday, October 2 report. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, August 4 report.

About 496,971 shares traded hands. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 52.17% since April 21, 2016 and is downtrending. It has underperformed by 57.50% the S&P500.

Insitutional Activity: The institutional sentiment increased to 1.82 in 2016 Q2. Its up 0.39, from 1.43 in 2016Q1. The ratio is positive, as 17 funds sold all Diplomat Pharmacy Inc shares owned while 46 reduced positions. 23 funds bought stakes while 67 increased positions. They now own 50.07 million shares or 2.77% more from 48.72 million shares in 2016Q1.

Ameriprise accumulated 249,788 shares or 0.01% of the stock. Blackrock Japan Company has invested 0% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO). Finemark National Bank has invested 0% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO). Teacher Retirement System Of Texas holds 0% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO) for 5,404 shares. Fmr Ltd holds 0.01% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO) for 1.12M shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 967 shares or 0% of its portfolio. Dimensional Fund Advsrs L P accumulated 36,788 shares or 0% of the stock. Impact Lc holds 32,768 shares or 0.54% of its portfolio. Envestnet Asset Incorporated has 0% invested in the company for 17,494 shares. Sentinel Asset Mngmt last reported 216,849 shares in the company. Comm Fincl Bank last reported 13,270 shares in the company. Redwood Ltd Liability Co owns 127,107 shares or 0.41% of their US portfolio. Timessquare Capital Mgmt Lc last reported 0.32% of its portfolio in the stock. Goldman Sachs Grp last reported 39,133 shares in the company. First Interstate Fincl Bank last reported 0% of its portfolio in the stock.

Insider Transactions: Since August 1, 2016, the stock had 0 buys, and 2 selling transactions for $1.04 million net activity. $440,794 worth of shares were sold by Kaddis Atheer A on Monday, August 1.

Diplomat Pharmacy, Inc. operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The company has a market cap of $944.62 million. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. It has a 29.64 P/E ratio. The Firm operates through specialty pharmacy services segment.

According to Zacks Investment Research, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.”

DPLO Company Profile

Diplomat Pharmacy, Inc. (Diplomat), incorporated on March 26, 1975, operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Firm operates through specialty pharmacy services segment. The Firm provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Firm offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).

More notable recent Diplomat Pharmacy Inc (NYSE:DPLO) news were published by: Fool.com which released: “Why Diplomat Pharmacy, Inc. Is Plunging Today” on November 03, 2016, also Prnewswire.com with their article: “Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Diplomat Pharmacy …” published on November 16, 2016, Fool.com published: “Why Diplomat Pharmacy, Inc. Shares Are Falling 13.6% Today” on October 26, 2016. More interesting news about Diplomat Pharmacy Inc (NYSE:DPLO) were released by: Businesswire.com and their article: “DPLO LOSS ALERT: Rosen Law Firm Reminds Diplomat Pharmacy, Inc. Investors of …” published on November 17, 2016 as well as Finance.Yahoo.com‘s news article titled: “Lawsuit for Investors in shares of Diplomat Pharmacy Inc (DPLO) announced by …” with publication date: November 16, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>